2023
Assi A, Karbanova, T, Alghawas L, Lim YXD, Trela-Larsen L, Usher C, Barry M, Walsh C. Surrogate measures and the health technology assessment of cancer drugs in Ireland: a retrospective analysis of EMA cancer drug indication approvals between 2017 and 2022 and recommendations made by the NCPE in Ireland. ISPOR Europe. Copenhagen 2023
O’Callaghan J, Tilson L, Fogarty E, McCullagh L. Clinical expert opinion to inform Health Technology Assessment in Ireland. Saint James’s Hospital Annual Staff Conference. Dublin. 2023
Morgan C, Carey N, White A. Semi-Automatic Processes for Systematic Literature Reviews Using Text-Mining and Classification Techniques. Conference on Applied Statistics in Ireland (CASI). Killarney. 2023. https://casi.ie/id2/
Varley A, McCullagh L, Barry M. A retrospective analysis of HTA outcomes for antimicrobial agents in Ireland. 9th Annual SPHeRE Network Conference. Dublin. 2023
Dempsey M, Nash G, Phedoti TJ, Ghazi I, McCullagh L, Barry M, Harte M, Walsh C. Identification of the Challenges and Potential Solutions Associated with the Use of Basket Trials in the Health Technology Assessment of Drugs. 9th Annual SPHeRE Network Conference. Dublin. 2023
2022
Leroy J, Varley A, McCullagh, Barry M. Estimating the cost of an outpatient department visit in the Irish public healthcare system. ISPOR Europe. Vienna 2022
Carvalho J, McCullagh L, O’Callaghan J. A Review of the Use of Clinical Expert Opinion to Inform Survival Curve Extrapolations in Single Technology Appraisals of New Cancer Drugs by NICE, UK. ISPOR Europe. Vienna. 2022
O’Callaghan J, Tilson L, McCullagh L, Barry M. Clinical Expert Opinion in Health Technology Assessment Submissions to a National HTA Agency in Ireland. ISPOR Europe. Vienna. 2022.
Varley A, McCullagh L, Barry M. A retrospective analysis of HTA outcomes for antimicrobial agents in Ireland. Faculty of Public Health Winter Scientific Meeting. Dublin. 2022
C Flynn et al. POSC58 Budget Impact of Pembrolizumab for Untreated or Unresectable Head and Neck Cancer in Ireland. Value in Health, https://doi.org/10.1016/j.jval.2021.11.463.
Carey N et al. Axicabtagene Ciloleucel for Relapsed/Refractory Diffuse Large B-Cell Lymphoma in the Irish Healthcare Setting: Cost-Utility and Value of Information Analysis. ISPOR Europe. Vienna. 2022.
McConnell D, McCullagh L, Usher C, Walsh C, Barry M and Adams R. MOVe-OUT: A Trial of Two Halves – the Impact of Heterogeneity on Cost-Effectiveness Outcomes for COVID-19. ISPOR Europe. Vienna. 2022.
C Flynn et al. POSC58 Budget Impact of Pembrolizumab for Untreated or Unresectable Head and Neck Cancer in Ireland. Value in Health, https://doi.org/10.1016/j.jval.2021.11.463.
Carey N et al. Axicabtagene Ciloleucel for Relapsed/Refractory Diffuse Large B-Cell Lymphoma in the Irish Healthcare Setting: Cost-Utility and Value of Information Analysis. ISPOR Europe. Vienna. 2022.
McConnell D, McCullagh L, Usher C, Walsh C, Barry M and Adams R. MOVe-OUT: A Trial of Two Halves – the Impact of Heterogeneity on Cost-Effectiveness Outcomes for COVID-19. ISPOR Europe. Vienna. 2022.
2021
Carey N et al. The Use of a Text-Mining Screening Tool for Systematic Review of Treatments for Relapsed/Refractory Diffuse Large B-Cell Lymphoma. HTAi Annual Meeting. Virtual. 2021. https://doi.org/10.1017/S0266462321000696
Carey N et al. The Impact of Discounting on the Cost Effectiveness of Tisagenlecleucel for Relapsed/Refractory Acute Lymphoblastic Leukaemia. Value in Health, Volume 25, Issue 1, S85 – S86 https://doi.org/10.1016/j.jval.2021.11.398
2020
Carey N et al. Expert Elicitation of Probabilistic Distributions to Inform Survival Modelling of CD19 CAR T-Cell Therapies. SMDM 18th Biennial European Conference.
Carey N et al. Expert Elicitation of Probabilistic Distributions to Inform Survival Modelling of CD19 Chimeric Antigen Receptor T-Cell Therapies. HTAi Annual Meeting. Beijing, China (held virtually). 2020.
Treanor R, Mc Veigh C, Carey N. An Analysis of the Transferability of National Health Technology Assessments of Axicabtagene Ciloleucel. ISPOR Europe 2020. Virtual. 2020. https://doi.org/10.1016/j.jval.2020.08.389
Mc Veigh C, Treanor R, Carey N. A Comparative Analysis of National Health Technology Assessments of Tisagenlecleucel (Kymriah®) for Relapsed/Refractory Diffuse Large B-Cell Lymphoma. ISPOR Europe 2020. Virtual. 2020. https://doi.org/10.1016/j.jval.2020.08.381
O’Connor T, Adams R, Carey N, White A. Expert Elicitation for Cost Effectiveness Analysis of CAR-T. Society for Medical Decision Making 18th Biennial European Conference. Berlin, Germany. 2020. https://doi.org/10.1177/0272989X20930859
Carey N et al. Expert Elicitation of Probabilistic Distributions to Inform Survival Modelling of CAR T-Cell Therapies. SPHeRE Network 6th Annual Conference. Dublin, Ireland. 2020.
McConnell D, Trela-Larsen L, Usher C and Adams R. Comparing Methods for Converting Cycle Lengths in Discrete Time Markov Models. Society for Medical Decision Making 18th Biennial European Conference. Berlin, Germany. 2020.
2019
Usher C et al. MCDA for orphan drugs in Ireland – a methodology ready to deliver? HTAi 2019 Annual Meeting in Cologne, Germany
Carey N et al. Evaluating the Quality and Risk of Bias in Overall Survival Outcomes from Non-Randomised CAR T-Cell Therapy Pivotal Trials. ISPOR Europe 2019. Copenhagen, Denmark. 2019. https://doi.org/10.1016/j.jval.2019.09.203
Carey N et al. Institutional Requirements For The Provision Of A Chimeric Antigen Receptor (CAR) T-Cell Service: A Rapid Review. HTAi 2019 Annual Meeting. Cologne, Germany: https://doi.org/10.1017/S0266462319001648
Gorry, C. et al. Pcn240 Potential Budget Impact of Adjuvant Treatments for Stage Iii Melanoma in Ireland. Value in Health, Volume 22, S482
Gorry, C. et al. PCN184 Economic Evaluation of Checkpoint Inhibitors for The Treatment of Advanced Melanoma In The Irish Healthcare Setting. Value in Health, Volume 22, S471 – S472
Lee, A. et al. PNS181 Submissions to A National HtA Agency in Ireland: Drugs with Designated Orphan Status. Value in Health, Volume 22, S792
Gorry, C. et al. PCN73 Economic Evaluation of Targeted Treatments for Brafv600 Positive Melanoma In The Irish Healthcare Setting. Value in Health, Volume 22, S449
Tilson L, Drummond M, Lowe E. Is delayed access due to issues of HTA capacity a necessary reality or an unacceptable problem? ISPOR Europe 2019. Copenhagen, Denmark.
2018
Trela-Larsen, L. Et Al. Pcn244 – Real-World Evidence on the Utilisation of Regorafenib in Ireland. Value in Health, Volume 21, S55
Mccabe, L. Et Al. Pcn272 – Analysis of Pharmacy Claims for High Cost Drugs: Lenalidomide Utilisation and Expenditure In Ireland. Value in Health, Volume 21, S60
Gorry C et al. Systematic Review of Cost-Effectiveness Studies of Melanoma Treatments. HTAi 2018 Annual Meeting in Vancouver, Canada.
Lamrock, F Et Al. Pmu25 – Examining The Consistency and Accuracy of the Budget Impact Models Submitted to The National Centre for Pharmacoeconomics in Ireland to Aid the Creation of an Applicant Template. Value in Health, Volume 21, S312
Carey, N Et Al. Prm272 – The Eunethta Transferability Tool: Application to Novel Treatments for Relapsed Refractory Multiple Myeloma in The Irish Healthcare Setting. Value in Health, Volume 21, S402 – S403
Gorry, C. et al. PCN353 – CONSTRUCT VALIDITY OF EQ-5D-3L IN NON-MELANOMA SKIN CANCER (NMSC). Value in Health, Volume 21, S74
2017
O’Donnell, H et al. Secondary Prevention Cardiovascular Patients In Ireland – Population Characteristics For Cost-Effectiveness Analysis. Value in Health, Volume 20, Issue 9, A602
Gorry, C et al. Analysis Of Hospital Episode Statistics To Identify Hospital Resource Use Due To Skin Cancer In Ireland. Value in Health, Volume 20, Issue 9, A506
Gorry, C et al. Comparison of Utility Values Implemented in Disease Models of Metastatic Melanoma. Value in Health, Volume 20, Issue 9, A447 – A448
Carey N et al. Comparative Analysis of Health Technology Assessments of Drugs for the Treatment of Multiple Myeloma. ISPOR Europe 2017. https://doi.org/10.1016/j.jval.2017.08.2100
2016
McCullagh, LM et al. Non-Parametric Approach to Estimating Expected Value of Perfect Information: The Usefulness of this Approach to a National HTA Agency. Value in Health, Volume 19, Issue 7, A489
Schmitz, S et al. The Quev Score: A Quantitative Evaluation of the Quality of Clinical Evidence in HTA. Value in Health, Volume 19, Issue 7, A499
2014
McCullagh, L.M. et al. HTA Informed Price Negotiations: Cost Savings to the Health Payer in Ireland. Value in Health, Volume 17, Issue 7, A420
2012
Adams R, Walsh C, Barry M, Fitzgerald O, Helliwell P. Mapping models in Psoriatic Arthritis: Analysis from the GRACE dataset. ISPOR Berlin Nov 5-7 2012.
McCullagh L, Walsh C, Barry M. Integration of Value of Information Into the Decision Making Process in Ireland. ISPOR 15th Annual European Congress, ICC Berlin in Berlin, Germany 3- 7 November 2012.
Fogarty E, Walsh C, Grehan S, Schmitz S, McGuigan C, Barry M, Tubridy N. Modelling the Relationship between Disease Severity and Utility in Multiple Sclerosis. ISPOR 15th Annual European Congress, November 2012, Berlin, Germany.
Fogarty E, Schmitz S, Walsh C, Barry M. Combining RCT and Observational Data in a Mixed Treatment Comparison of Disease-Modifying-Therapies for Multiple Sclerosis. ISPOR 15th Annual European Congress, November 2012, Berlin, Germany.
McGreal-Bellone A, Cleary S, Farrell G, Bergin C, Barry M, Kieran J. Health-Related Quality of Life in HIV/HCV Co-Infected Patients in Ireland. ISPOR 15th Annual European Congress. November 2012, Berlin, Germany.
Kieran J, Mushtaq H, Bergin C, Norris S, Barry M. Demographics and Health-State Utilities of Irish Patients with Hepatitis C Infection; Use of the 5-Level Eq-5d Questionnaire. ISPOR 15th Annual European Congress, November 2012, Berlin, Germany.
Fogarty E, Walsh C, Schmitz S, McGuigan C, Barry M, Tubridy N. The Impact of Increasing Disability on Quality of Life in Multiple Sclerosis. ECTRIMS 28th congress, October 2012, Lyon, France.
Fogarty E, Walsh C, McGuigan C, Barry M, Tubridy N. The Impact of Increasing Disability on Quality of Life in Multiple Sclerosis. Irish Neurological Association Meeting. May 2012, Cork, Ireland.
2011
McCullagh L, Usher C, Barry M. A review of the primary care prescribing of dabigatran etexilate and rivaroxaban in Ireland. ISPOR. 14th Annual European Congress, 5-8 November 2011, Madrid, Spain.
Fogarty E., Tilson L., Barry M. Cost of symptomatic drug therapy in multiple sclerosis Value in Health 2011 14:7 (A321) ISPOR 14th Annual European Congress, 5-8 November 2011, Madrid, Spain.
S Schmitz, R Adams, C Walsh, M Barry, O FitzGerald. A Bayesian Mixed Treatment Comparison Demonstrates Differences Between Anti-Tumour Necrosis Factor Agents in Rheumatoid Arthritis. ACR Nov 4-9 2011, Chicago
Usher C, Tilson L, Bennett K, Barry M. Evaluation of cost containment interventions introduced on the community drug schemes in Ireland using a national prescription claims database. ISPOR. 14th Annual European Congress, 5-8 November 2011, Madrid, Spain.
Usher C, Tilson L, Bennett K, Barry M. Evaluation of expenditure trends in Ireland. PPRI. 2nd Annual Conference, 29-30 September 2011, Vienna, Austria.
Usher C, Bennett K, Barry M. Introduction of a prescription charge on the community drug scheme in Ireland – what impact has it had on drug utilization? ISPOR. 14th Annual European Congress, 5-8 November 2011, Madrid, Spain.
2010
Usher C, Tilson L, Barry M. Potential future impact of price control mechanisms on the community drug schemes in Ireland. HTAi. 7th Annual Meeting, 6–9th June 2010, Dublin, Ireland.
McCullagh L, Walsh C, Barry M. An application of Value of Information analysis to decrease uncertainty. HTAi. 7th Annual Meeting, 6–9th June 2010, Dublin, Ireland.
McCullagh L, Walsh C, Barry M. Prioritising further research using the expected value of perfect information: Application to venous thromboembolism prophylaxis after total hip replacement. ISPOR. 13th Annual European Congress 7-10 November 2010. Prague, Czech Republic.
Cahir C. Fahey T. Teljeur C. Tilson L. Bennett K. Cost-effective proton pump inhibitor prescribing: Potential strategies for more rational Prescribing. Pharmacoepidemiology and Drug Safety (2010) 19 SUPPL. 1 (S217-S218).
Wettermark B. Elseviers M. Godman B. Ronning M. Tilson L. Palcevski V.V. Methodological challenges in cross-national comparisons of drug utilization. Pharmacoepidemiology and Drug Safety (2010) 19 SUPPL. 1 (S16).
R. Adams, B. Craig , C. Walsh , B. Bresnihan, M. Barry , D. Veale , O. FitzGerald. Revising THE Scoring System FOR THE Eq-5d Produces a Change IN Qaly, Which is Closer to Disease Measures in Inflammatory Arthritis. EULAR 2010
2009
Adams R., Teck Ng C., Lynch B., Saber T., Pontiflex E., Barry M., Molloy M., Grier A., Veale D., Bresnihan B., FitzGerald O. QOL Scores reflect disease activity both pre and post initiation of biologic therapy in patients with rheumatoid and psoriatic arthritis Rheumatology 2009 48 SUPPL. 1 (i158)
Adams R., Walsh C., Tilson L., FitzGerald O., Bresnihan B., Veale D., Barry M. A calibration of the relationship between the HAQ, The SF-6D and the EQ-5D in inflammatory arthritis
Value in Health 2009 12:7 (A446-A447)
McCullagh L, Tilson L, Walsh C, Barry M. Cost-effectiveness of rivaroxaban and dabigatran etexilate for the prophylaxis of venous thromboembolism and associated long term complications after total hip replacement in Ireland. ISPOR. 12th Annual European Congress, 24-27 October 2009, Paris, France.
Sharp L. Tilson L. Whyte S. O’Ceilleachair A. Walsh C. Usher C. Tappenden. P. Chilcott J. Staines A. Comber H. Barry M. Cost-effectiveness of a population-based colorectal cancer screening programme in Ireland. Value in Health (2009) 12:7 (A280).
Tilson L. O’Leary A. Usher C. Barry M. A review of pharmoeconomic evaluations of new and existing technologies by the national centre for pharmoeconomics in Ireland. Value in Health (2009) 12:7 (A250).
Heghes D.A. Tilson L. Drummond M.F. Estimating drug costs in economic evaluations in Ireland and the UK: An analysis of practice and research recommendations. Value in Health (2009) 12:3 (A6-A7).
R. C. Adams, A. Mumtaz, D. Veale, B. Bresnihan, M. Barry, O. FitzGerald. Improvement in quality of life is demonstrated by improvement in bath disease activity scores. Eular2009
